Search Results

You are looking at 41 - 50 of 370 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Dung T. Le and Elizabeth M. Jaffee

antigen-specific T cells and other agents to block T-cell inhibitory signals. Commercial grade agents are available or will become available to test in combinations. Examples include: 1) bevacizumab; 2) celecoxib; 3) GCS-100; 4) GC-1008; 5

Full access

Thomas Kaley and Louis B. Nabors

-refractory meningiomas represents an unmet clinical need. There are no FDA-approved therapies. The NCCN Guidelines suggest sunitinib, interferon alfa, or bevacizumab plus everolimus as category B recommendations.” RANO Review “This review was based on 43 publications on

Full access

Eric T. Wong and Steven Brem

: 347 – 356 . 2. Folkman J . Tumor angiogenesis: therapeutic implications . N Engl J Med 1971 ; 285 : 1182 – 1186 . 3. Willett CG Boucher Y di Tomaso E . Direct evidence that the VEGF-specific antibody bevacizumab has

Full access

William T. McGivney

Recent decisions about the optimal frequency and population age for screening mammography and the appropriate uses of bevacizumab and sipuleucel-t have raised questions, if not concerns, about both the decision-making processes and the level of

Full access

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, Mitesh Borad, Daniel Brown, Adam Burgoyne, Prabhleen Chahal, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, Lipika Goyal, William G. Hawkins, Renuka Iyer, Rojymon Jacob, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Vaibhav Sahai, Tracey Schefter, Gagandeep Singh, Stacey Stein, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole R. McMillian, Cindy Hochstetler, and Susan D. Darlow

against lenvatinib alone for the frontline treatment of unresectable or metastatic HCC ( identifier: NCT03713593). Atezolizumab and Bevacizumab Bevacizumab, a VEGF inhibitor, has modest clinical activity as a single agent or in

Full access

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. 1 Lastly, improved

Full access

Emil Lou, Donna D'Souza, and Andrew C. Nelson

carcinoembryonic antigen (CEA) biomarker while on combination chemotherapy (FOLFIRI with bevacizumab), bevacizumab was discontinued in favor of initiating an EGFR inhibitor (panitumumab) while continuing the FOLFIRI backbone. This alteration to her treatment

Full access

Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong

Practice Guidelines in Oncology for Rectal Cancer recommendations for the management of potentially resectable synchronous metastatic disease Describe the role of chemotherapy with bevacizumab in the conversion of CRLM to resectable status Case

Full access

or metastatic disease that progresses following initial therapy with 5-FU/leucovorin plus bevacizumab. The following parameters were added for reporting of pathologic stage: lymphovascular invasion, perineural invasion, and extra nodal tumor

Full access

Andrew H. Ko and Margaret A. Tempero

: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society